In this first episode, Peter and Rita discuss how the pandemic has accelerated market shifts already in play, disrupting current business models and dramatically altering how pharma business will be done in the future.
Throughout this discussion Peter poses the following questions to Rita – capitalizing on her extensive experience working strategically with pharmaceutical and medical device manufacturers, payers, and providers – in order to get some answers on what the road ahead will look like:
Healthcare systems in the U.S. are estimated to lose hundreds of billions of dollars due to Covid-19. How will these losses and other pandemic-related consequences impact the pharma industry?
Some clinical trials are being delayed due to Covid-19. How do you see clinical studies and the broader R&D agenda being impacted by this ‘new normal’?
From your work with health systems, healthcare providers, and payers, what do you think the long-term impacts of Covid-19 on commercial models and manufacturer relationships will be?
What learnings can the pharmaceutical industry take away from other industries, such as financial services and utilities, that have successfully negotiated massive change?
If you are an executive looking for practical advice on how to respond to COVID-19 or are simply seeking cutting-edge insights for longer-term business strategies in the face of the pandemic, this discussion will be of value to you.
Share this webinar!
Simply provide a few short details and you can watch this episode
About the speakers
About Rita Numerof and Numeroff & Associates
Rita E. Numerof, PhD, President of Numerof & Associates, is an internationally recognized consultant and author with more than 30 years of experience in the field of strategy development and execution, business model design, and market analysis. Numerof works globally with pharmaceutical and medical device manufacturers, payers, and providers to develop and implement strategic solutions responsive to today’s dynamic business environment. Numerof helps their clients meet the challenges of development and commercialization – including strategy, market access, health economics, stakeholder analysis and value narrative development, and market evaluation.
About Peter Hempshall and Deallus
Peter Hempshall is a career consultant and business leader. Over the past twelve years, Peter has successfully led a series of global companies and strategic business units, specializing in competitive intelligence; business insights; commercial strategy and market access. Peter cut his teeth in business strategy and leadership during the financial crisis of 2008. He became CEO of Deallus, a life sciences consulting firm with a strong heritage in competitive intelligence, in 2019. Deallus works closely with pharmaceutical and biotech companies in order to offer thought partnership and strategic intelligence that shapes and refines strategies for competitive advantage.
Upcoming topics in this discussion series
A look at what’s ahead in the Navigating Market Disruption series:
Leading in a Crisis – Driving value for your customers, your organization, and yourself
Maneuvering complex change in clinical trials
- Building supply chain capabilities for the changing marketplace
The long-term impacts of COVID-19 on commercial models and manufacturer relationships